|Day Low/High||120.40 / 122.48|
|52 Wk Low/High||74.51 / 122.48|
Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is keeping an eye on quarterly results from Valeant Pharmaceuticals on Tuesday.
Icahn may have a tough time finding interest in this behemoth.
Snap Inc. is preparing for the biggest technology IPO since Alibaba in 2014.
I started the day with a discussion of the new administration's policies and why I believe there are headwinds to their passage over the next few months or quarters. I covered last evening's Procter & Gamble short for a profit. "For Traders Only."...
Jim Cramer compares Allergan's growth to other pharma stocks.
Two industries should largely be avoided under this administration: pharma and retail.
Eli Lilly reaffirms its 2017 guidance after reporting higher sales and earnings in its latest quarter.
I had my most active day of the year trading. It was also my most profitable. Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead. I started the day with a story re...
Animal health and oncology deal activity is heating up in 2017.
I wrote in my 15 Surprises for 2017 that Mr. Market may make a yearly high in the first two weeks of January. We are now wrapping up that period -- and I plan to expand my relatively small short exposure. In other words, I am sticking to my script...
Slow day, at meetings all morning. Despite the strength in our currency (and its adverse implications on multi-national profitability), there was no follow-through to yesterday's schmeissing. I reflected on my July call that we have hit a Genera...
For the first time in three years, Eli Lilly's guidance for next year has topped Wall Street's consensus estimates.
Eli Lilly shares are up after the drugmaker offered 2017 earnings guidance above Wall Street's forecast.
Shares of Eli Lilly were higher Tuesday after announcing that starting January of 2017, customers will be able to purchase insulin at a discount of up to 40%.
Shares of Biogen soared Friday after the biotech company's early clinical trial data of its experimental Alzheimer's drug was leaked and Eli Lilly's study failed.
What a strange day -- maybe even ominous. This table tells it all. The divergences I have been mentioning this week intensified today, with the technology-laden Nasdaq taken out to the shed and the Russell 2000 Index trading lower for the third...
It may be time to embrace the contrary. First issue (!!): The Palm Beach Chronicles. My weekly (brief) technical review of the markets -- cooling off ahead? BTIG's Stockton is bullish and so, as I have expressed, are most others! Campbell ...
'Milestone payments' could boost deal's $125 million announced price.
The worst appears to be over for this sector; we could see big growth ahead.
"If you work for a living, why the hell do you kill yourself working?" -- Tuco the Ugly" The Good, the Bad and the Ugly" I further added to my short exposure today in a quiet, pre-Thanksgiving trading session. And now it's time to run down "The Good...
I'm still bullish, but I'm looking over my shoulder to see if there are some bears sneaking up.
These 'wing and a prayer' stocks are full of surprises.
It will likely take several months of base building before LLY looks better on the charts.
U.S. stocks pulled back Wednesday, from their record highs on Tuesday, when the Dow Jones Industrial Average crossed 19,000 and the S&P 500 topped 2,200.
Here are two extremes. Eli Lilly down nearly $12, or more than 15%, in pre-market trading on the failure of Solanezumab to meet its primary endpoint. And Deere up $9, or more than 10%, in the pre-market on a giant earnings beat.